CVS Health Corporation (CVS) is a diversified U.S. health services company spanning retail pharmacy, the Caremark pharmacy benefit manager, the Aetna health insurer, and the Oak Street Health primary-care business. It trades on the NYSE and is a stock, not an exchange-traded fund.
The $113 central target is a calculated average of 18 verified analyst targets, not an official published consensus. The targets range from HSBC's $103 (a Hold) to UBS's $126, a spread of roughly 22% that reflects genuine disagreement about how durable the recent earnings recovery will be. Most firms cluster in the $107–$120 band: for example, BofA's Allen Lutz set $110 (October 13), Leerink Partners $112 (October 12), TD Cowen $110 (October 9), RBC Capital $113 (October 7), Bernstein $112 (October 5), JPMorgan $118, UBS $126, and Wells Fargo $123.
Notably, several firms have trimmed targets even while keeping Buy ratings. BofA lowered its target to $110 from $120, and Leerink cut to $112 from $119, signaling that near-term enthusiasm has cooled even as the broader Street rating remains firmly positive. The dominant thesis among bulls is that the Medicare Advantage (MA) margin recovery in Aetna is real and can re-rate the stock higher.
With the stock near $90.25, reaching $113 would require a rise of roughly 25%, a substantial move. The path would likely depend on continued earnings beats and margin expansion in the healthcare benefits segment, which analysts view as the main engine. CVS has beaten profit estimates in recent quarters and raised its full-year 2026 guidance twice, while its MBR improved dramatically from 94.8% in late 2025 to the mid-80s percent range during 2026. At a forward P/E (price-to-earnings ratio) near 10–11 times estimated earnings, the valuation still leaves room for multiple expansion if execution holds.
The stock has pulled back roughly 18% from its July 2026 52-week high near $110.68, so the $113 target sits just above that prior peak. The 200-day moving average near $88.79 has acted as a support zone, while the 50-day average near $91.23 and the psychologically important $100 level are nearer-term markers. A durable resistance zone sits between roughly $110 and $111, the prior high area, meaning the target requires not just recovery but a breakout to new highs.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ. The next major catalyst is CVS's earnings report on November 4, followed by guidance, MBR trends, analyst target revisions, and developments in MA rate-setting and pharmacy regulation. Any change in the pace of the Aetna margin recovery is likely to be the single most important swing factor for the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For those seeking a data-driven edge in names like CVS, these AI-generated signals offer a practical way to stay ahead of evolving market structure.
The $113 target is a calculated average of 18 analyst targets, requiring a substantial gain of about 25% from the current price near $90.25. The case for reaching it rests on a genuine recovery in Aetna's insurance margins, repeated earnings beats, raised guidance, and an inexpensive forward valuation. The case against it centers on PBM and retail headwinds, high leverage, and a wide analyst range from $103 to $126 that shows the Street is not unanimous about the durability of the turnaround. Whether the stock can reach $113 will likely be decided by the upcoming earnings report and the trajectory of the medical benefit ratio rather than by the consensus number itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CVS has been loosely correlated with UNH. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if CVS jumps, then UNH could also see price increases.